Gapping up
In reaction to strong earnings/guidance: VRA +19.8%, PRGN +8.7%, HRB +7.1%, (announces bank divestiture transaction now closed; announces new a $3.5 billion share repurchase program, modified Dutch auction), GIII +4.6%, QIHU +3.9%, BOBE +0.7%
M&A news: SURG +49.2% (to be acquired by Valeant Pharmaceuticals (VRX) for $6.50 per share in cash)
Select metals/producers trading higher: CAS +10.3%, BHP +2.4%, X +2%, RIO +1.9%, FCX +1.7%, AA +1.5%
Other news: ETRM +43.4% (announces that analyses of the ReCharge Study demonstrated Excess Weight Loss of 34% and significant improvements in obesity-related risk factors for vBloc Therapy treated, moderately obese patients who had at least one comorbidity), BVXV +37.5% (announces the intention of the NIAID, to launch a Phase 2 trial of its Multimeric-001 vaccine), ASTI+28.6% (still checking; stock closed at $0.21 yday), FLXN +15.8% ( announces FDA fast track designation for its FX006 candidate), WMGI +11.3% ( announces FDA approval for its Premarket Approval Application of its Augment Bone Graft), LOXO +7.3% (granted orphan drug designation by the FDA for LOXO-101 for treatment of patients with soft tissue sarcoma), TRVN +7.2% (cont strength), PBMD +4.7% (cont strength), TSRO +3.9% (FDA approval for Varubi), SUNE +3.8% (cont strength), TASR +3.6% (USPTO has rejected 20 claims of a patent assigned to Digital Ally (DGLY)), AZN +2.2% (enters license agreement to develop FluMist in Japan), XGTI +1.9% (announces the commercial availability of its xMax NOW transportable broadband wireless system), TSLA+1.8% (rebounding with broader mkt), JCP +1.7% (cont strength), GSK +1.6% (Nikkei Asian Review discusses that GlaxoSmithKline (GSK) Hep C vaccine supplies may have been impacted by explosion in China), BABA +1.4% (rebounding with broader mkt), SGMO +1.3% (Sangamo BioSci and Shire plc (SHPG) revise their collaboration and license agreement to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease), ALU +1.2% (still checking), CELG +1.1% (favorable commentary on Monday's Mad Money), AMGN +1% (Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide), GM +1% (rebounding with broader mkt)
Analyst comments: CVEO +7.5% (upgraded to Buy at Sterne Agee CRT ), WIX +7% (upgraded to Buy at Deutsche Bank ), ARMH +3.1% (upgraded to Neutral at JP Morgan), PHG +1.9% (upgraded to Outperform at RBC Capital Mkts), WYNN +1.9% (upgraded to Buy at Credit Agricole), GIS +1.6% (upgraded to Equal-Weight at Morgan Stanley), TXT +1.4% (upgraded to Buy at Citigroup),T +1.4% (upgraded to Buy from Neutral at Citigroup), PYPL +1.2% (initiated with a Buy and $42 price target at Argus), DIS +1% (initiated with a Outperform at Credit Agricole
)
In reaction to strong earnings/guidance: VRA +19.8%, PRGN +8.7%, HRB +7.1%, (announces bank divestiture transaction now closed; announces new a $3.5 billion share repurchase program, modified Dutch auction), GIII +4.6%, QIHU +3.9%, BOBE +0.7%
M&A news: SURG +49.2% (to be acquired by Valeant Pharmaceuticals (VRX) for $6.50 per share in cash)
Select metals/producers trading higher: CAS +10.3%, BHP +2.4%, X +2%, RIO +1.9%, FCX +1.7%, AA +1.5%
Other news: ETRM +43.4% (announces that analyses of the ReCharge Study demonstrated Excess Weight Loss of 34% and significant improvements in obesity-related risk factors for vBloc Therapy treated, moderately obese patients who had at least one comorbidity), BVXV +37.5% (announces the intention of the NIAID, to launch a Phase 2 trial of its Multimeric-001 vaccine), ASTI+28.6% (still checking; stock closed at $0.21 yday), FLXN +15.8% ( announces FDA fast track designation for its FX006 candidate), WMGI +11.3% ( announces FDA approval for its Premarket Approval Application of its Augment Bone Graft), LOXO +7.3% (granted orphan drug designation by the FDA for LOXO-101 for treatment of patients with soft tissue sarcoma), TRVN +7.2% (cont strength), PBMD +4.7% (cont strength), TSRO +3.9% (FDA approval for Varubi), SUNE +3.8% (cont strength), TASR +3.6% (USPTO has rejected 20 claims of a patent assigned to Digital Ally (DGLY)), AZN +2.2% (enters license agreement to develop FluMist in Japan), XGTI +1.9% (announces the commercial availability of its xMax NOW transportable broadband wireless system), TSLA+1.8% (rebounding with broader mkt), JCP +1.7% (cont strength), GSK +1.6% (Nikkei Asian Review discusses that GlaxoSmithKline (GSK) Hep C vaccine supplies may have been impacted by explosion in China), BABA +1.4% (rebounding with broader mkt), SGMO +1.3% (Sangamo BioSci and Shire plc (SHPG) revise their collaboration and license agreement to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease), ALU +1.2% (still checking), CELG +1.1% (favorable commentary on Monday's Mad Money), AMGN +1% (Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide), GM +1% (rebounding with broader mkt)
Analyst comments: CVEO +7.5% (upgraded to Buy at Sterne Agee CRT ), WIX +7% (upgraded to Buy at Deutsche Bank ), ARMH +3.1% (upgraded to Neutral at JP Morgan), PHG +1.9% (upgraded to Outperform at RBC Capital Mkts), WYNN +1.9% (upgraded to Buy at Credit Agricole), GIS +1.6% (upgraded to Equal-Weight at Morgan Stanley), TXT +1.4% (upgraded to Buy at Citigroup),T +1.4% (upgraded to Buy from Neutral at Citigroup), PYPL +1.2% (initiated with a Buy and $42 price target at Argus), DIS +1% (initiated with a Outperform at Credit Agricole
)